Translating Evidence to Practice: A Case-Based Approach to VTE Prevention, Diagnosis & Management
Faculty: Samuel Goldhaber, MD, | Ruth B. Morrison, RN, BSN, CVN | James B. Groce, III, PharmD, CACP | Sylvia McKean, MD
CME credit hour: 2.0
This case-based educational program will help you to identify and discuss pertinent clinical data for the treatment and prevention of VTE, as well as demonstrate how these data can be interpreted and applied into clinical practice. This would include discussion of current issues and controversies surrounding management of VTE, identifying risk factors for VTE, the treatment and secondary prophylaxis in VTE, treatment options for the management of acute PE, as well a special consideration for the medically ill or patients with comorbidities. By reviewing specific patient cases, our esteemed faculty will provide concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE.

Current Therapeutic Trends in the Treatment of Chemotherapy-Induced Anemia
Faculty: Leon E. Cosler, RPh, PhD | John Glaspy, MD, MPH | Gary H. Lyman, MD, MPH, FRCP (Edin) | Christopher R. Friese, RN, PhD, AOCN^®
CME / CE credit hours: 1.5
Anemia is common in cancer patients, but the impact is often poorly appreciated. It is a major cause of tumor hypoxia, a condition that can further tumor survival and malignant progression and also reduces the effectiveness of several anticancer therapies, including radiotherapy and oxygen-dependent cytotoxic agents. Strategies for incorporating clinical guidelines into practice and the safety and pharmacoeconomic issues surrounding treatment of anemia with ESPs will be discussed in this activity.

Management of Febrile Neutropenia and Anemia in Chemotherapy Patients: Clinical Practice Guidelines Update
Faculty: Dwight Kloth, PharmD, FCCP, BCOP
CME / CE credit hour: 1.0
Despite data showing the positive impact of treating febrile neutropenia and anemia in chemotherapy patients, a majority of patients still do not receive proper treatment. The European Cancer Anemia Survey (ECAS) reported that over 60% of the cancer-associated anemia patients did not receive any treatment for their anemia. Moreover, approximately 60,000 cancer patients are hospitalized annually with febrile neutropenia in the United States. This program will address strategies for treating chemotherapy induced anemia and febrile neutropenia, including identifying patients at risk and available treatment agents. Additionally, a review of the updated practice guidelines from ASCO, NCCN and EORTC and their practical applications will be discussed.

Chemotherapy-Induced Neutropenia Prevention: Implications of New Clinical Data and Guidelines
Faculty: Jeffrey C. Crawford, MD | David C. Dale, MD | Gary H. Lyman, MD, MPH, FRCP (Edin) | Christopher R. Friese, RN, PhD, AOCN^®
CME / CE credit hour: 1.0
Chemotherapy-induced neutropenia has very serious and important clinical consequences in terms of medical care, quality of life, and economic factors for cancer treatment. Chemotherapy patients who develop neutropenia are at risk of developing febrile neutropenia, which is a medical emergency that requires immediate medical management. Febrile neutropenia has historically been treated through the use of prophylactic antibiotics, but their usefulness continues to be controversial and the incidence of febrile neutropenia continues to be high. The use of hematopoetic colony stimulating factors (CSFs) has improved the outcomes for patients who experience febrile neutropenia.

Applying Evidence to Practice: Recent Advances in the Management of Chemotherapy-Induced Neutropenia
Faculty: Christopher R. Friese, RN, PhD, AOCN^® | Joan M. Giblin, MSN, APRN-BC, AOCN^® | Rebecca B. Donohue, MSN, RNCS, FNP, AOCN^®, APNG | Anne Doyle, RN, MSN
CE credit hour: 1.0
Neutropenia is the major dose-limiting toxicity associated with cancer chemotherapy and febrile neutropenia is associated with considerable morbidity, mortality, and cost. Colony Stimulating Factors, or CSFs, are used to reduce the severity and duration of chemotherapy-induced neutropenia and diminish the risk of febrile neutropenia and infection for patients receiving chemotherapy. The risk of neutropenia varies depending on the agent used and dose delivered. Predictive factors of febrile neutropenia have been identified for several types of malignancies. Identification of these risk factors when chemotherapy is planned can support the appropriate use of CSFs to reduce the risk of febrile neutropenia for patients.

Challenges in Dosing Low Molecular Weight Heparin
(Accreditation Expired)
Faculty: Joseph F. Dasta, MSc., FCCM, FCCP | Steven M. Hollenberg, MD | Sandra L. Kane-Gill, PharmD., MSc. | Arthur P. Wheeler, MD
CME Credit hour: 1.0
This program features a discussion between four experts in critical care medicine. The discussion addresses the challenges in dosing and monitoring patients at the extremes of body weight, patients with renal insufficiency, and critically ill patients with altered plasma volume, as well as the pharmacoeconomics of Low Molecular Weight Heparins.

Real World Best Practices for DVT Prophylaxis
(Accreditation Expired)
Faculty: Paul E. Marik, MD, FCCP, FCCM | Arthur P. Wheeler, MD, FCCP | Jamie E. Siegel, MD | Sandra L. Kane-Gill, PharmD, MSc.
CME Credit hours: 1.5
Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the United States. There exists a gap in knowledge for the treatment of VTE with secondary prophylaxis, acute PE, as well as a special consideration for the critically ill (e.g. volume overloaded) or patients with comorbidities (e.g. renal insufficiency). Furthermore, the existing clinical data needs to be discussed and interpreted in order to be applied, as well as a discussion surrounding current issues and controversies in VTE treatment and prophylaxis. This program provides concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE.

Chemotherapy-Induced Neutropenia: Impact, Risks & Prevention (Accreditation Expired)
Faculty: David C. Dale, MD | Michael Rader, MD | Robert E. Smith, MD | Christopher R. Friese, RN, PhD
CME Credit hour: 1.0
Three of the nation's leading specialists will discuss the efficacy and appropriate use of myeloid growth factors for the prevention of chemotherapy-induced neutropenia and febrile neutropenia.

All information content within shall be considered confidential property of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.